Bracco Diagnostic Imaging

Bracco Diagnostics, Inc. develops and markets clinical agents for use in X-ray/computed tomography, nuclear medicine, and magnetic resonance imaging (MRI) in the United States and Canada. Its products for X-ray/computed tomography include Isovue, an iopamidol injection; Gastrografin, an iodinated radiopaque contrast medium for oral or rectal administration; Cholografin Meglumine, an iodipamide meglumine injection for intravenous cholangiography and cholecystography; Sinografin, a diatrizoate meglumine and iodipamide meglumine injection for use in hysterosalpingography; and Cystografin, a diatrizoate meglumine injection for retrograde cystourethrography. The company’s products for MRI consists of ProHance, a gadolinium-based MRI contrast agent; and MultiHance, a MRI contrast agent to demonstrate weak and transient interactions with serum proteins. Its products for nuclear medicine includes CardioGen-82, a generator-based myocardial perfusion agent; Kinevac, a cholecystopancreatic-gastrointestinal peptide hormone for parenteral administration; Choletec for use as a hepatobiliary imaging agent in cholescintigraphy; MDP-Bracco for use as a bone imaging agent; Chromitope sodium for use in determining red blood cell volume or mass, and studying its survival time; and Bracco A-C-D Solution Modified for use with chromitope sodium in the labeling of red blood cells. In addition, the company provides products for gastroenterology, which encompass a mouthpiece for protection during EGD procedures; components for GI endoscopy; mouthpieces to reduce the risk of hypoxia; in-line suction polyp traps; and polyp retrieval products, as well as offers contrast agents for ultrasound procedures. Further, Bracco Diagnostics offers professional services to health care professionals. It offers its products through a network of representatives. The company was founded in 1994 and is based in Princeton, New Jersey. Bracco Diagnostics, Inc. operates as a subsidiary of Bracco S.p.A.